Available Clinical Research in the Care of Patients with NSCLC with an EGFR Mutation

Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation
Proceedings from a live event on May 31, 2024, held during the ASCO 2024 Annual Meeting.
Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:
• Introduction (0:00)
• Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation - Dr Langer (2:08)
• Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation - Dr Goldman (22:37)
• Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation - Dr Yu (43:23)
• Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation - Dr Sabari (1:03:33)
• Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation - Dr Piotrowska (1:20:15)
• Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation - Dr Neal (1:38:44)
The full program, slides, CME information and select publications:
www.researchto...